16 matches for your search in the start-up spotlight
rss
Shorten research and development time for cancer drugs from 3 years to 12 months and significantly reduce development costs
24-Mar-2025
The German-Swiss biotechnology start-up BioCopy has secured new capital of 8 million euros. This sum is an important step for the company on its mission to produce more effective cancer drugs in the shortest possible time and at significantly lower costs. The company is supported by a group of ...
"BioCopy is able to accelerate the development time from a decade long marathon to a fast sprint"
11-Apr-2024
BioCopy AG, a research-based biotechnology company headquartered in Basel, Switzerland, announced the acquisition of Perspix Biotech GmbH. Founded in 2021 and based in Frankfurt am Main, Germany, Perspix Biotech with its end-to-end automated platform roPROTix combines artificial intelligence and ...
21-Jun-2023
In spring 2023, RIANA Therapeutics, a spin-off of Vetmeduni, kicked off its operations. With the aim of developing innovative cancer therapeutics, this biotech start-up leverages groundbreaking scientific insights from Vetmeduni's Unit of Functional Cancer Genomics. A significant milestone has ...
Thermosome Receives Regulatory Approval for First-In-Human Trial with its Lead Program THE001
04-Apr-2023
Thermosome announced that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) and the responsible Ethics Committee to conduct a Phase 1 trial with its lead program THE001 in Germany. Patient enrollment is expected to start in Q2, 2023. The primary ...
Viennese start-up develops novel, precise anti-cancer drugs
06-Mar-2023
RIANA Therapeutics, a promising pharmaceutical start-up recently spun out of the University of Veterinary Medicine Vienna (Vetmeduni), aims to develop novel therapeutics for cancer patients based in part on scientific findings from Vetmeduni’s Moriggl research group (Moriggl Lab). The ...
Belgian biotech start-up will use funding to start first-in-human clinical study for lead drug candidate in lung cancer
23-Jan-2023
DeuterOncology, a clinical-stage drug development company, announces the closing of its €5.65 million ($6.1M) Series A financing, with participation from historical investor Newton Biocapital and new investors Noshaq and Investsud Tech. This funding will enable the company to start the phase I ...
A grand total of 26 spin-offs were founded at ETH Zurich in 2022
10-Jan-2023
Their businesses range from new cancer drugs and sustainable water bottles to digital mapping of urban traffic flows. The ETH spin-off family also welcomed three new unicorns and raised 1.2 billion Swiss francs in fresh capital. These newly founded spin-offs cover a wide variety of fields and ...
European Union-Funded Project to Result in Novel Treatment Approaches for Several Solid Tumor Types
12-Sep-2022
Indivumed GmbH and CELLphenomics GmbH announced a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets. The new platform combines Indivumed’s AI-driven oncology analytics with CELLphenomics’ expertise in creating organoid models to ...
06-Jun-2022
Repare Therapeutics Inc. announced it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related ...
28-Mar-2022
R-nuucell is one of the 50 companies distinguished by the Women_TechEU pilot program, an unprecedented initiative by the European Union. The funding obtained will allow the continuation of the CanceRusolution project, through which this spin-off has been studying a drug to treat triple negative ...
